Novartis

Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed

Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 2. Please see detailed guidance ...
Novartis

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility

At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to ...
Novartis

Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants

Coartem Baby was developed by Novartis with the scientific and financial support of MMV, and as part of the PAMAfrica ...
Novartis

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1 Well-controlled ...
Novartis

Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030

Scales program footprint from 11 countries to more than 30 by 2030, including across five cities in the U.S. Builds on pilot programs that demonstrated significant increase in control rates for high ...
Novartis

Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
Novartis

Product Listing in Singapore

Below is a list of the treatments we currently offer via our Innovative Medicines Division. Visit Sandoz and Advanced Accelerator Applications to learn about our generics and radiopharmaceutical ...
Novartis

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
Novartis

J.P. Morgan Healthcare Conference 2026

No Offer or Solicitation This communication is for informational purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or ...
Novartis

Career Search

Albania Algeria Angola Argentina Armenia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bolivia Bosnia and Herzegovina Brazil Bulgaria Burkina Faso ...
Novartis

Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result ...
Novartis

Novartis begins construction of two new radioligand therapy facilities in the US, expanding its world-class RLT manufacturing and supply network

Indianapolis site expansion will establish in-house production of isotopes critical for production of radioligand therapies (RLTs) for cancer treatment Novartis is exploring a diverse portfolio of new ...